VYNE Therapeutics's market cap is currently $39.83M. The company's EPS TTM is $-0.851; its P/E ratio is ―; VYNE Therapeutics is scheduled to report earnings on February 27, 2025, and the estimated EPS forecast is $-0.30. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 424.00K	$ 477.00K	$ 14.76M	$ 20.99M	$ 443.00K
Gross Profit	$ 424.00K	$ 477.00K	$ 11.41M	$ 19.60M	$ 93.00K
Operating Income	$ -29.26M	$ -34.30M	$ -68.03M	$ -113.47M	$ -76.24M
EBITDA	$ -29.26M	$ -34.22M	$ -38.94M	$ -251.09M	$ -94.08M
Net Income	$ -28.45M	$ -33.95M	$ -73.33M	$ -255.57M	$ -70.46M
Balance Sheet
Cash & Short-Term Investments	$ 93.25M	$ 30.91M	$ 42.25M	$ 58.59M	$ 76.94M
Total Assets	$ 97.69M	$ 40.76M	$ 67.05M	$ 93.74M	$ 79.17M
Total Debt	$ 214.00K	$ -349.00K	$ 349.00K	$ 34.78M	$ 700.00K
Net Debt	$ -30.41M	$ -31.26M	$ -41.90M	$ -22.78M	$ -30.08M
Total Liabilities	$ 8.95M	$ 9.56M	$ 18.41M	$ 56.25M	$ 10.66M
Stockholders' Equity	$ 88.73M	$ 31.20M	$ 48.64M	$ 37.49M	$ 68.51M
Cash Flow
Free Cash Flow	$ -25.34M	$ -29.20M	$ -56.37M	$ -137.19M	$ -65.11M
Operating Cash Flow	$ -25.34M	$ -29.20M	$ -56.37M	$ -137.08M	$ -65.10M
Investing Cash Flow	$ -57.35M	$ 15.67M	$ 1.03M	$ 89.11M	$ 41.37M
Financing Cash Flow	$ 82.39M	$ 1.65M	$ 39.78M	$ 61.81M	$ 4.99M

Currency in USD

VYNE Therapeutics Earnings and Revenue History

Income Statement >

VYNE Therapeutics Debt to Assets

Balance Sheet >

VYNE Therapeutics Cash Flow

Cash Flow >

VYNE Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing